VivoSeq
Respiratory

Pleural Effusion

42

Pipeline Programs↗

10

Active Trials↗

23

Companies Involved↗

Pleural effusion is a moderately active landscape with 42 programs across 23 companies. The most active players are Candel Therapeutics, Inc., Sichuan Clover Biopharmaceuticals, Inc., Roche. 1 therapy is approved with 5 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

58/100

Pipeline Velocity

15/100

Mech. Concentration

18/100

Completion Rate

75/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Candel Therapeutics, Inc.

1 program

Phase 1S

Sichuan Clover Biopharmaceuticals, Inc.

1 program

Phase 1Roche logo

Roche

1 program

Phase 1Astellas logo

Astellas

1 program

Phase 1W

Wuhan YZY Biopharma Co., Ltd.

2 programs

Phase 2R

RS Oncology LLC

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical5

Bleomycin Sulfate

Sequus Pharmaceuticals

Cytokine

Peking University Cancer Hospital & Institute

Recombinant Human Interleukin-2

Second Xiangya Hospital of Central South University

Microparticles Packaging Methotrexate (mps-MTX)

Peking Union Medical College

Intrapleural Medications

Swedish Medical Center

Phase 18

Camrelizumab

Sun Yat-sen University

Docetaxel

Avyxa

GL-ONC1

Genelux Corporation

Alteplase

Roche

Adv-Tk

Candel Therapeutics, Inc.

Phase 223

Cisplatin

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Nivolumab

Bristol-Myers Squibb

Carboplatin

Avyxa

Gemcitabine

Johnson & Johnson

Dexamethasone

Aspen Global Incorporated

Phase 35

Bevacizumab

Bio-Thera Solutions

Doxycycline

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Endostar，cisplatin

Jiangsu Simcere Pharmaceutical Co., Ltd.

Iodopovidone

Universidad Tecnológica de Pereira

Abnoba Viscum F

Abnoba Korea

Approved1

Talc

Sciarra

Analysis

Modality Breakdown

80%

Small molecule

40 of 50 classified programs — the dominant modality here.

20%ALL OTHERSProtein / enzyme48%Monoclonal antibody36%Cell therapy24%Gene therapy12%

Small molecule leads; the ring shows all 50 classified programs, each share of the total. Modality classified for 100% of 55 pipeline programs.

Analysis

Trial Status

56

clinical trials

Completed21 · 38%
Unknown status18 · 32%
Recruiting6 · 11%
Terminated6 · 11%
Not yet recruiting3 · 5%
Withdrawn1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

56 trials

IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites
Recruiting·—·Phase 1·NCT05268172·40 enrolled
Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06184321·30 enrolled
Indwelling Pleural Catheters With or Without Doxycycline in Treating Patients With Malignant Pleural Effusions
Recruiting·MM.D. Anderson Cancer Center·N/A·NCT03465774·208 enrolled
A Phase Ib Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion
Recruiting·JJemincare·Phase 1·NCT06740019·30 enrolled
Effectiveness and Safety of Sodium Bicarbonate Pleural Lavage in the Treatment of Complex Pleural Effusion
Recruiting·FFirst Affiliated Hospital of Ningbo University·N/A·NCT06734481·260 enrolled
OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.
Recruiting·OOdense University Hospital·Phase 1·NCT06421610·20 enrolled
A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions
Active, not recruiting·Jiangsu Simcere Pharmaceutical Co., Ltd. logoJiangsu Simcere Pharmaceutical Co., Ltd.·Phase 3·NCT04914598·290 enrolled
Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors
Not yet recruiting·—·Phase 1·NCT07443020·10 enrolled
First-in-Human Expanded Cohort Study of Intrapleural Administration of TolueneSulfonamide in Patients With Malignant Pleural Effusion
Not yet recruiting·—·Phase 1/2·NCT07332858·105 enrolled
Dual-function Semirigid Thoracoscopy Versus Rigid Thoracoscopy for the Diagnosis of Pleural Disease: a Randomised Controlled Trial
Not yet recruiting·CChina-Japan Friendship Hospital·Preclinical·NCT07114783·92 enrolled
Ph I:Bevacizumab + Chemotherapy in Pts w/Malig Pleural Effusion Due to Adv NSCLC
Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00250978·15 enrolled
Intrapleural Instillation of the Nivolumab in Cancer Patients With Pleural Effusion.
Completed·KKidney Cancer Research Bureau·Phase 2·NCT04749602·26 enrolled
Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion
Completed·PPeking University Cancer Hospital & Institute·N/A·NCT01256801·36 enrolled
Persistent Pleural Effusion Treatment Following Cardiothoracic Surgery by Platelet-Fibrin Glue
Completed·—·Phase 2·NCT06449131·19 enrolled
Randomized Study Comparing Pleural Drainage by Videothoracoscopy to Medical Drainage in Infectious Pleural Effusion
Completed·UUniversity Hospital, Rouen·N/A·NCT01994499·45 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)